Literature DB >> 2667788

Treatment of rhabdomyosarcoma and other malignant mesenchymal tumours of childhood with ifosfamide + vincristine + dactinomycin (IVA) as front-line therapy (a SIOP study).

J Otten1, F Flamant, C Rodary, M Brunat-Mentigny, L Dutou, D Olive, E Quintana, P A Voûte.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2667788     DOI： 10.1007/bf00253236

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  3 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Growth hormone and segmental growth in survivors of head and neck embryonal rhabdomyosarcoma.

Authors:  J R Katz; P Bareille; G Levitt; R Stanhope
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

3.  High-dose VP16 cisplatinum in soft tissue sarcoma of children.

Authors:  M Grabois; D Frappaz; E Bouffet; C Carrie; D Bouhour; T Philip; M Brunat-Mentigny
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.